• Consensus Rating: Hold
  • Consensus Price Target: $34.83
  • Forecasted Upside: 26.07 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.3 (-1.07%)

This chart shows the closing price for ANAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AnaptysBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANAB

Analyst Price Target is $34.83
▲ +26.07% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $34.83, with a high forecast of $44.00 and a low forecast of $28.00. The average price target represents a 26.07% upside from the last price of $27.63.

This chart shows the closing price for ANAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in AnaptysBio. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2022JPMorgan Chase & Co.Boost TargetUnderweight$24.00 ➝ $32.00Low
11/9/2022WedbushBoost Target$21.00 ➝ $32.00Low
11/9/2022Raymond JamesBoost TargetOutperform$30.00 ➝ $38.00Low
11/1/2022GuggenheimUpgradeNeutral ➝ Buy$44.00Low
9/19/2022HC WainwrightReiterated RatingBuy$35.00Low
9/13/2022Truist FinancialDowngradeBuy ➝ Hold$50.00 ➝ $28.00Low
9/6/2022WedbushLower Target$24.00Low
9/1/2022Raymond JamesLower Target$35.00 ➝ $30.00Low
8/31/2022Raymond JamesInitiated CoverageOutperform$35.00Low
3/22/2022GuggenheimDowngradeBuy ➝ NeutralHigh
3/14/2022WedbushReiterated RatingNeutralMedium
3/7/2022WedbushLower TargetNeutral$35.00 ➝ $33.00High
3/7/2022HC WainwrightBoost TargetBuy$43.00 ➝ $46.00Medium
10/26/2021HC WainwrightReiterated RatingBuy$44.00Low
10/26/2021WedbushBoost TargetNeutral$25.00 ➝ $32.00Low
10/4/2021HC WainwrightReiterated RatingBuy$43.00High
9/27/2021HC WainwrightReiterated RatingBuy$43.00Low
8/18/2021WedbushBoost TargetPositive ➝ Neutral$20.00 ➝ $25.00High
8/10/2021HC WainwrightReiterated RatingBuy$43.00Low
6/22/2021HC WainwrightInitiated CoverageBuy$43.00High
5/20/2021UBS GroupInitiated CoverageNeutral$29.00Low
3/16/2021Truist FinancialUpgradeHold ➝ Buy$27.00 ➝ $34.00Low
3/15/2021WedbushReiterated RatingOutperform ➝ NeutralN/A
3/9/2021WedbushDowngradeOutperform ➝ NeutralMedium
3/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
2/11/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$19.00 ➝ $40.00Low
10/27/2020Truist FinancialBoost Target$20.00 ➝ $27.00High
10/27/2020WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $35.00High
10/14/2020Truist FinancialBoost Target$16.00 ➝ $20.00High
10/14/2020GuggenheimUpgradeNeutral ➝ Buy$36.00High
5/7/2020Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $16.00High
5/6/2020Stifel NicolausReiterated RatingHold$17.00Low
3/3/2020SunTrust BanksLower TargetHold$15.00 ➝ $14.00High
3/2/2020Stifel NicolausReiterated RatingHold$18.00Low
11/8/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$12.00N/A
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$109.00 ➝ $17.00N/A
11/8/2019WedbushDowngradeOutperform ➝ NeutralN/A
11/8/2019GuggenheimDowngradeBuy ➝ NeutralN/A
11/8/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
10/3/2019Credit Suisse GroupLower TargetNeutral$75.00 ➝ $48.00Low
10/1/2019WedbushReiterated RatingOutperformHigh
9/30/2019Stifel NicolausReiterated RatingHoldHigh
8/20/2019Cantor FitzgeraldSet TargetBuy$140.00High
8/12/2019Stifel NicolausSet TargetHold$63.00Medium
8/9/2019Credit Suisse GroupLower TargetNeutral$79.00 ➝ $75.00High
6/24/2019HC WainwrightSet TargetBuy$126.00High
6/24/2019SunTrust BanksLower TargetBuy$125.00 ➝ $93.00High
6/21/2019Stifel NicolausDowngradeBuy ➝ Hold$124.00 ➝ $74.00High
6/21/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$137.00 ➝ $79.00High
5/8/2019Stifel NicolausSet TargetBuy$124.00High
4/2/2019Cantor FitzgeraldSet TargetBuy$140.00High
4/2/2019Stifel NicolausSet TargetBuy$124.00High
3/26/2019Cantor FitzgeraldReiterated RatingBuy$140.00High
3/1/2019WedbushReiterated RatingOutperformMedium
2/27/2019Cantor FitzgeraldReiterated RatingBuy$140.00Low
2/22/2019GuggenheimInitiated CoverageBuy$135.00High
1/18/2019SunTrust BanksLower TargetBuy$125.00Medium
12/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$126.00High
12/3/2018Cantor FitzgeraldSet TargetBuy$140.00Medium
11/21/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$115.00High
11/11/2018Stifel NicolausSet TargetBuy$127.00Medium
11/9/2018Credit Suisse GroupSet TargetBuy$143.00N/A
11/9/2018Cantor FitzgeraldSet TargetBuy$140.00N/A
10/16/2018Cantor FitzgeraldReiterated RatingBuy$140.00High
9/27/2018Credit Suisse GroupSet TargetOutperform ➝ Buy$104.00 ➝ $147.00Low
9/22/2018Cantor FitzgeraldSet TargetBuy$124.00High
9/18/2018WedbushReiterated RatingOutperform$138.00Low
9/16/2018Cantor FitzgeraldSet TargetBuy$124.00High
9/14/2018Stifel NicolausSet TargetBuy$127.00Low
9/4/2018Cantor FitzgeraldInitiated CoverageBuy$124.00Low
8/27/2018Cantor FitzgeraldInitiated CoverageOverweight$124.00Medium
8/15/2018JMP SecuritiesLower TargetMarket Outperform ➝ Buy$180.00 ➝ $153.00Low
8/8/2018Royal Bank of CanadaReiterated RatingHold$84.00Low
8/7/2018Jefferies Financial GroupReiterated RatingBuy$121.00Low
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$104.00High
4/4/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$144.00 ➝ $40.00High
3/27/2018JMP SecuritiesSet TargetBuy$180.00Low
3/27/2018WedbushReiterated RatingOutperform$151.00High
3/26/2018Stifel NicolausSet TargetBuy ➝ Buy$139.00 ➝ $152.00High
3/6/2018Stifel NicolausBoost TargetBuy ➝ Buy$130.00 ➝ $139.00Medium
3/2/2018Royal Bank of CanadaBoost TargetOutperform$144.00Low
2/20/2018WedbushReiterated RatingOutperform ➝ Outperform$142.00High
2/19/2018Jefferies Financial GroupBoost TargetBuy$6.59 ➝ $145.00High
2/15/2018SunTrust BanksBoost TargetBuy ➝ Buy$115.00 ➝ $162.00Low
1/23/2018Credit Suisse GroupSet TargetOutperform ➝ Outperform$85.00 ➝ $135.00Medium
1/19/2018Robert W. BairdReiterated RatingBuy$81.00 ➝ $144.00High
12/18/2017Royal Bank of CanadaBoost TargetOutperform$108.00Medium
(Data available from 12/1/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 6 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
AnaptysBio logo
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More

Today's Range

Now: $27.63
Low: $26.86
High: $28.50

50 Day Range

MA: $27.67
Low: $24.52
High: $30.97

52 Week Range

Now: $27.63
Low: $18.20
High: $37.40


604,354 shs

Average Volume

253,899 shs

Market Capitalization

$785.58 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of AnaptysBio?

The following Wall Street research analysts have issued stock ratings on AnaptysBio in the last twelve months: Guggenheim, HC Wainwright, JPMorgan Chase & Co., Raymond James, StockNews.com, Truist Financial Co., and Wedbush.
View the latest analyst ratings for ANAB.

What is the current price target for AnaptysBio?

6 Wall Street analysts have set twelve-month price targets for AnaptysBio in the last year. Their average twelve-month price target is $34.83, suggesting a possible upside of 26.1%. Guggenheim has the highest price target set, predicting ANAB will reach $44.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $28.00 for AnaptysBio in the next year.
View the latest price targets for ANAB.

What is the current consensus analyst rating for AnaptysBio?

AnaptysBio currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ANAB, but not buy more shares or sell existing shares.
View the latest ratings for ANAB.

What other companies compete with AnaptysBio?

How do I contact AnaptysBio's investor relations team?

AnaptysBio's physical mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 362-6295 and its investor relations email address is [email protected] The official website for AnaptysBio is www.anaptysbio.com. Learn More about contacing AnaptysBio investor relations.